$0.05
(Market cap
$7 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
0.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-15.7
-
Face value
--
-
Shares outstanding
1,926,345
6 Years Aggregate
CFO
$-286.62 Mln
EBITDA
$-327.07 Mln
Net Profit
$-373.33 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bolt Biotherapeutics (BOLT)
| -26.3 | 0.9 | -23.3 | -21.5 | -43.2 | -59.2 | -- |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Bolt Biotherapeutics (BOLT)
| -48.9 | -51.9 | -13.8 | -73.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bolt Biotherapeutics (BOLT)
|
4.0 | 7.4 | 4.7 | -28.7 | -611.5 | -146.8 | -- | 0.6 |
| 82.3 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.8 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 55.3 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.1 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.0 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.5 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 585.6 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 348.6 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.9 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated... antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California. Read more
-
CEO & Director
Dr. Randall C. Schatzman Ph.D.
-
CEO & Director
Dr. Randall C. Schatzman Ph.D.
-
Headquarters
Redwood City, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Bolt Biotherapeutics (BOLT)
What is the current share price of Bolt Biotherapeutics (BOLT) Today?
The share price of Bolt Biotherapeutics (BOLT) is $4.03 (NASDAQ) as of 01-Sep-2026 12:31 EDT. Bolt Biotherapeutics (BOLT) has given a return of -43.22% in the last 3 years.
What is the current PB & PE ratio of Bolt Biotherapeutics (BOLT)?
Since, TTM earnings of Bolt Biotherapeutics (BOLT) is negative, P/E ratio is not available.
The P/B ratio of Bolt Biotherapeutics (BOLT) is 0.61 times as on 28-Aug-2026, a 88 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.31 |
0.39 |
2024 |
-0.02 |
0.02 |
2023 |
-0.03 |
0.02 |
2022 |
-0.03 |
0.01 |
2021 |
-0.09 |
0.04 |
What is the 52 Week High and Low of Bolt Biotherapeutics (BOLT)?
The 52-week high and low of Bolt Biotherapeutics (BOLT) are Rs 7.20 and Rs 3.13 as of 01-Sep-2026.
What is the market cap of Bolt Biotherapeutics (BOLT)?
Bolt Biotherapeutics (BOLT) has a market capitalisation of $ 7 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Bolt Biotherapeutics (BOLT)?
Before investing in Bolt Biotherapeutics (BOLT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.